Literature DB >> 24108322

Deciphering logopenic primary progressive aphasia: a clinical, imaging and biomarker investigation.

Marc Teichmann1, Aurélie Kas, Claire Boutet, Sophie Ferrieux, Marie Nogues, Dalila Samri, Christina Rogan, Didier Dormont, Bruno Dubois, Raffaella Migliaccio.   

Abstract

Within primary progressive aphasia the logopenic variant remains less understood than the two other main variants, namely semantic and non-fluent progressive aphasia. This may be because of the relatively small number of explored patients and because of the lack of investigations with a comprehensive three-level characterization of cognitive, brain localization and biological aspects. The aim of the present study was to decipher the logopenic variant through a multimodal approach with a large cohort of 19 patients (age 66.5 ± 8.7 years, symptom duration 3.2 ± 0.6 years) using detailed cognitive and linguistic assessments, magnetic resonance imaging and perfusion single-photon emission computed tomography as well as cerebrospinal fluid biomarkers screening for Alzheimer pathology. The linguistic assessment unveiled that language dysfunction is not limited to the typical feature of word finding and verbal working memory impairments but that it extends into the language system affecting to some degree syntactic production, phonological encoding and semantic representations. Perfusion tomography revealed damage of the temporal-parietal junction with a peak of significance in the superior temporal gyrus (Brodmann area 42), and of some less significant prefrontal areas (Brodmann areas 8, 9 and 46), whereas hippocampal cortices were unaffected. Magnetic resonance imaging, which was visually assessed in a larger group of 54 patients with logopenic, non-fluent, semantic variants as well as with posterior cortical atrophy, confirmed that the logopenic variant demonstrates predominant atrophy of left temporal-parietal junction, but that this atrophy pattern has a relatively poor sensitivity and specificity for clinical diagnosis. Finally, the biomarker study revealed that two-thirds of the logopenic patients demonstrated a profile indicative of Alzheimer pathology whereas one-third had a non-Alzheimer profile. Splitting the two groups showed that logopenic aphasia due to probable Alzheimer pathology is a more aggressive variant characterized by more extensive language/cognitive disorders affecting, in addition to lexical processes and verbal working memory, also phoneme sequencing, semantic processing and ideomotor praxis. Concordantly, logopenic aphasia due to probable Alzheimer pathology demonstrated more extensive brain hypoperfusion involving larger regions throughout the inferior parietal, the posterior-superior and the middle temporal cortex. These findings allow for unfolding logopenic aphasia into two subvariants differing by disease severity, lesion nature and lesion distribution, which has important implications for diagnosis, patient management and for potential future trials with anti-Alzheimer drugs. The present data therefore provide novel insight into the cognition and brain damage of logopenic patients while unveiling the existence of distinct diseases constituting a 'logopenic aphasia complex'.

Entities:  

Keywords:  Alzheimer’s disease; logopenic progressive aphasia; logopenic subvariants; temporal-parietal junction

Mesh:

Substances:

Year:  2013        PMID: 24108322     DOI: 10.1093/brain/awt266

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  55 in total

Review 1.  The Wernicke area: Modern evidence and a reinterpretation.

Authors:  Jeffrey R Binder
Journal:  Neurology       Date:  2015-11-13       Impact factor: 9.910

2.  Sleep talking and primary progressive aphasia: case study and autopsy findings in a patient with logopenic primary progressive aphasia and dementia with Lewy bodies.

Authors:  Alexandra Clemans Apple; Qinwen Mao; Eileen Bigio; Borna Bonakdarpour
Journal:  BMJ Case Rep       Date:  2019-05-27

Review 3.  Pathology in primary progressive aphasia syndromes.

Authors:  Jennifer M Harris; Matthew Jones
Journal:  Curr Neurol Neurosci Rep       Date:  2014-08       Impact factor: 5.081

4.  Amyloid and FDG-PET study of logopenic primary progressive aphasia: evidence for the existence of two subtypes.

Authors:  Jordi A Matías-Guiu; María Nieves Cabrera-Martín; Teresa Moreno-Ramos; María Valles-Salgado; Marta Fernandez-Matarrubia; José Luis Carreras; Jorge Matías-Guiu
Journal:  J Neurol       Date:  2015-04-11       Impact factor: 4.849

5.  Treatment for Word Retrieval in Semantic and Logopenic Variants of Primary Progressive Aphasia: Immediate and Long-Term Outcomes.

Authors:  Maya L Henry; H Isabel Hubbard; Stephanie M Grasso; Heather R Dial; Pélagie M Beeson; Bruce L Miller; Maria Luisa Gorno-Tempini
Journal:  J Speech Lang Hear Res       Date:  2019-08-07       Impact factor: 2.297

Review 6.  Primary Progressive Aphasia and Stroke Aphasia.

Authors:  Murray Grossman; David J Irwin
Journal:  Continuum (Minneap Minn)       Date:  2018-06

Review 7.  Primary progressive aphasia: a model for neurodegenerative disease.

Authors:  Boon Lead Tee; Maria Luisa Gorno-Tempini
Journal:  Curr Opin Neurol       Date:  2019-04       Impact factor: 5.710

8.  Bilingualism in Primary Progressive Aphasia: A Retrospective Study on Clinical and Language Characteristics.

Authors:  Ana S Costa; Regina Jokel; Alberto Villarejo; Sara Llamas-Velasco; Kimiko Domoto-Reilley; Jennifer Wojtala; Kathrin Reetz; Álvaro Machado
Journal:  Alzheimer Dis Assoc Disord       Date:  2019 Jan-Mar       Impact factor: 2.703

9.  Aphasic variant of Alzheimer disease: Clinical, anatomic, and genetic features.

Authors:  Emily Rogalski; Jaiashre Sridhar; Benjamin Rader; Adam Martersteck; Kewei Chen; Derin Cobia; Cynthia K Thompson; Sandra Weintraub; Eileen H Bigio; M-Marsel Mesulam
Journal:  Neurology       Date:  2016-08-26       Impact factor: 9.910

Review 10.  Case Studies Illustrating Focal Alzheimer's, Fluent Aphasia, Late-Onset Memory Loss, and Rapid Dementia.

Authors:  Gamze Balci Camsari; Melissa E Murray; Neill R Graff-Radford
Journal:  Neurol Clin       Date:  2016-06-03       Impact factor: 3.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.